Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV
infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or
a higher dose every 12 hours.